Trial Profile
Phase I/II Trial of Vandetanib in Combination With Metformin in Subjects With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Vandetanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 12 Jan 2021 Status changed from completed to discontinued.
- 07 Feb 2020 Status changed from recruiting to completed.
- 15 Jul 2015 New trial record